Soyez toujours en bonne forme et soyez réussi, comme Oleg Taktarov!La brillante étoile de la constellation InstaSpot!

L'acteur, le champion de l'UFC et un vrai bogatyr russe! . Homme qui ne doit sa réussite qu'à lui-même. L'homme qui est sur la même route que nous suivons. Le secret du succès de Taktarov est le progrès permanent vers la réalisation de son objectif.
Découvrez toutes les facettes de votre talent! Apprenez, essayez, commettez des erreurs, mais ne vous arrêtez pas!

InstaSpot - L'histoire de votre succès commence ici !

For Traders

Charts

#BIIB

#BIIB (Biogen Inc.). Taux de change et graphiques en ligne.

#BGNE Return to the list of instruments #BMY

Currency converter

156.29 USD
26 Nov 2024 18:26

$-0.03
(-0.02%)

Prev Close

$158.36

Open

$159.88

Day's High

$159.73

Day's Low

$155.9

Week High

$159.77

Week Low

$155.9

Download archive

Open the chart in full screen view

Download archive

Open the chart in full screen view

Biogen Inc. About company

Biogen Inc. is an American biopharmaceutical company founded in 1978. Initially, the company was headquartered in Switzerland, with all studies being conducted in European countries. Later, most of the company’s research centers were moved to the United States.

Biogen Inc. is engaged in the production of drugs based on DNA studies. At present, the company produces drugs used to treat multiple sclerosis, SMA, Alzheimer's disease, and other disorders.

Biogen’s market cap is $38.33 billion. Last year, its annual revenue stood at $10.981 billion, with net income at $1.556 billion.

Biogen’s shares and factors affecting their value

Its stock has been listed on the NASDAQ exchange under the ticker BIIB since 1983. The initial share price was $23.

Today, the company's shares are worth $257-$267. Over the past year, their value has ranged from $187 to $291.

When trading Biogen’s stock, traders are recommended to keep track of:

The products manufactured by the drugmaker are in demand. Moreover, their relevance is bound to increase in the future due to the world's aging population as well as progressive diseases among the elderly;
If the company passes clinical trials and receives a patent for a drug, it provides itself with an opportunity to make profits for at least 12 years, while other companies are prohibited from releasing analogues;
If Aducanumab receives approval as a treatment for Alzheimer's disease, the company’s capitalization will increase several times;
The company has good prospects in the market as it is greatly underestimated in comparison to competitors.

InstaSpot – choix de millions!Et cela a plus de poids que toute parole!

Soyez toujours en bonne forme et soyez réussi, comme Oleg Taktarov!La brillante étoile de la constellation InstaSpot!

#BIIB (Biogen Inc.). Taux de change et graphiques en ligne.

Currency converter

Biogen Inc. About company

Biogen’s shares and factors affecting their value